Production of Allergen Fusion Protein for Allergy Vaccines
Author Information
Author(s): Ilk Nicola, Schumi Christian-Thomas, Bohle Barbara, Egelseer Eva Maria, Sleytr Uwe B
Primary Institution: University of Natural Resources and Life Sciences (BOKU), Vienna
Hypothesis
Can a recombinant S-layer/allergen fusion protein be produced in Bacillus subtilis without endotoxin contamination for use in allergy immunotherapy?
Conclusion
The study successfully produced a pyrogen-free recombinant S-layer/allergen fusion protein that shows potential for vaccine development against atopic allergies.
Supporting Evidence
- The recombinant protein was shown to be secreted into the culture medium without endotoxin.
- Immunoblotting confirmed the presence of allergen-specific IgE binding.
- Electron microscopy revealed self-assembly of the fusion protein in suspension.
Takeaway
Scientists made a special protein that can help treat allergies without causing fevers, using a safe type of bacteria.
Methodology
The S-layer/allergen fusion protein was expressed in Bacillus subtilis using E. coli-B. subtilis shuttle vectors, followed by immunoblot analysis and electron microscopy.
Limitations
The study did not quantify the exact immune response or long-term efficacy of the produced protein in clinical settings.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website